SCHEMBL74711

SCHEMBL74711

COC(=O)C1CCC[N]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2786350 1.00
SCHEMBL2783866 1.00
SCHEMBL1219868 0.94 SMN1; SMN2 (0.37)
SCHEMBL3362858 0.94 SMN1; SMN2 (0.37)
SCHEMBL4196872 0.78 GAA (0.35)
SCHEMBL4200760 0.78 GAA (0.35)
SCHEMBL1049438 0.78 ALDH1A1 (0.39)
SCHEMBL1901073 0.78 GAA (0.35)
SCHEMBL7599702 0.78 TSHR (0.33)
SCHEMBL7286186 0.75 PPM1B (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4017841-A1 PIGMENTED AND FLUORESCENT COMPOUNDS DERIVED FROM THE ADDITION OF A PRIMARY OR SECONDARY AMINE TO AN ALDEHYDE Regents of the University of Minnesota (US) 2022-06-29 EP claimed
CN-109311860-B Xanthone derivatives for the treatment or prevention of hepatitis B virus diseases 豪夫迈·罗氏有限公司 2022-04-08 CN claimed
CN-108137547-B Heterocyclic compounds useful as TNF alpha modulators 百时美施贵宝公司 2021-11-12 CN claimed
EP-3464278-B1 XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE HOFFMANN LA ROCHE (CH) 2021-06-16 EP claimed
WO-2021035176-A1 PIGMENTED AND FLUORESCENT COMPOUNDS DERIVED FROM THE ADDITION OF A PRIMARY OR SECONDARY AMINE TO AN ALDEHYDE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2021-02-25 WO claimed
US-10865191-B2 Heterocyclic compounds useful as modulators of TNF alpha BRISTOL-MYERS SQUIBB COMPANY (US) 2020-12-15 US claimed
US-10611748-B2 Xanthone derivatives for the treatment of hepatitis B virus disease HOFFMANN-LA ROCHE INC. (US) 2020-04-07 US claimed
US-20190185444-A1 XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE HOFFMANN-LA ROCHE INC. (US) 2019-06-20 US claimed
EP-3464278-A1 XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE H. Hoffnabb-La Roche Ag (CH) 2019-04-10 EP claimed
US-20180222883-A1 HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF TNF ALPHA BRISTOL MYERS SQUIBB CO (US) 2018-08-09 US claimed
WO-2003004468-A1 COMPOUNDS HAVING PROLYL OLIGOPEPTIDASE INHIBITORY ACTIVITY, METHODS FOR THEIR PREPARATION AND THEIR USE ORION CORPORATION (FI) 2003-01-16 WO claimed
WO-2002074758-A2 NOVEL AMINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS ABBOTT LABORATORIES (US) 2002-09-26 WO claimed
US-20020022039-A1 Method of using alpha-keto enamine derivatives as ingredients and products incorporating same NESTEC S.A. (CH) 2002-02-21 US claimed
EP-0582789-B1 Novel 7-(substituted)-8-(substituted)-9-(substituted glycyl)amido-6-demethyl-6-deoxytetracyclines AMERICAN CYANAMID CO (US) 2001-10-04 EP claimed
WO-1999062905-A1 8-PHENYLXANTHINE DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS ALMIRALL PRODESFARMA, S.A. (ES) 1999-12-09 WO claimed
US-5102882-A Nootropic agents NIPPON SHINYAKU CO., LTD. (JP) 1992-04-07 US claimed
US-4845113-A USEFUL IN RADICAL SCAVENGING THERAPY BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) 1989-07-04 US claimed
EP-0297816-A2 Homocyclostatine and cyclostatine containing polypeptides as antihypertensive agents PFIZER INC. (US) 1989-01-04 EP claimed
US-4749687-A Renin inhibitors containing statine or derivatives thereof PFIZER INC. (US) 1988-06-07 US claimed
EP-0155809-A2 Renin inhibitors containing statine or derivatives thereof PFIZER INC. (US) 1985-09-25 EP claimed